Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...
Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...
Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...
Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...
Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...
Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from ...
On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...
The therapy, branded as Bizengri, targets the NRG1 gene, which is associated with formation and progression of several tumors ...
FDA approves Merus' Bizengri for advanced pancreatic adenocarcinoma and NSCLC with NRG1 fusion, showing ORRs of 40% and 33%. Bizengri approval based on eNRGy trial data; DOR in pancreatic ...